Any policy views, whether explicitly stated, inferred or interpreted from the contents of this publication, should not be represented as reflecting the views of Agriculture and Agri-Food Canada. Aussi disponible en français sous le titre de : ABSTRACT " A Methodology to Evaluate the Impact of Cost Recovery in Canadian Agriculture and Agri-food Chains " This publication is a technical report des...

BACKGROUND Several countries in sub-Saharan Africa have recently adopted policies that remove user fees for facility-based delivery services. There is little rigorous evidence of the impact of these policies on utilization of delivery services and no evaluations have examined effects on neonatal mortality rates (NMR). In this article, we estimate the causal effect of removing user fees on the p...

T he fourth iteration of the 1992 law that allows the U.S. Food and Drug Administration to levy user fees on drug companies contains several reforms that could create a major change in how the agency monitors the safety of new drugs after they enter the market. Lawmakers are using reauthorization of the Prescription Drug User Fee Act (PDUFA) to overhaul the agency's authorities and responsibili...

OBJECTIVE Analysis of the implementation process for a national user fees abolition policy aimed at children under age five organized in Niger since October 2006. METHODS This was a study of contrasted cases. Two districts were selected, Keita and Abalak; Keita is supported by an international NGO. In 2009, we carried out socio-anthropological surveys in all the health facilities of both dist...

The two most important aspects of openness have to do with free availability over the internet and as few restrictions as possible on the use of the resource. There should be no technical barriers (undisclosed source code), no price barriers (subscriptions, licensing fees, pay-perview fees) and as few legal permission barriers as possible (copyright and licensing restrictions) for the end-user....

n engl j med 367;14 nejm.org october 4, 2012 1277 legislators, and patient advocates. The driving force behind the legislation was the need to reauthorize statutorily defined user fees that pharmaceutical manufacturers (since 1992) and medical-device manufacturers (since 2002) have paid when they submitted applications to the FDA for the evaluation of new products. The bill sailed through a clo...